ICE-HBV is growing and developing new organisational policies: you can find the confidentiality policy and industry engagement policy under Publications.
Governance structure and systems are being revised too, in consultation with our stakeholders.
ICE-HBV is growing and developing new organisational policies: you can find the confidentiality policy and industry engagement policy under Publications.
Governance structure and systems are being revised too, in consultation with our stakeholders.
ICE-HBV members T. Jake Liang and Anna Kramvis hosted the 2017 International HBV Meeting in on September 3-7 in Washington D.C., USA.
ICE-HBV Annual Scientific assembly was he held there on September 7.
Dr. Francis Chisari will receive the inaugural Distinguished Award in Hepatitis B Research.
Capucine Penicaud is presenting ICE-HBV at the Australasian Viral Hepatitis Elimination Conference on August 10 in Cairns, Australia.
Stephen Locarnini is presenting ICE-HBV on August 8 at the World Indigenous Peoples’ Conference on Viral Hepatitis in Anchorage, Canada.
To participate to World Hepatitis Day campaign, please create your own poster using this link and send it to info@ice-hbv.org or tweet @ICE_HBV
2-2:45pm – Session 1 – Vaccines – the Most Effective Route to Elimination?
Co-Chairs: Peter Revill (Doherty Institute) and Helen Tyrell (Hepatitis Australia)
2:45-3:45pm – Session 2 – Test & Treat – Update and Challenges to Roll-Out
Co-Chairs: Mike Catton (Doherty Institute) and Melanie Eagle (Hepatitis Victoria)
4:00-4:45pm – Session 3 – HBV & Migrants
Chair: Benjamin Cowie (Doherty Institute)
4:50-5:45pm – Session 4 – Global Collaborations to Cure CHB
Chair: Anne Kelso (NHMRC)
5:45-6:00pm – Session 5 – Progress made in the roll-out of Victoria viral hepatitis strategies , The Honorable Frank McGuire, Parliamentary Secretary for Medical research
General Abstracts
http://www.hbvmeeting.org/abstracts-and-travel-grants/abstract-submission/
ICE-HBV and the WHO Collaborating Centre for Viral Hepatitis at the Peter Doherty Institute for Infection and Immunity are organising a World Hepatitis Day symposium entitled From Vaccine to Cure: The Road to Viral Hepatitis Elimination.
Join us on 28 July from 2pm to 6pm, in person or online via Zoom. Please register here: https://goo.gl/2noLVa (free). Check the preliminary programme.
To participate to World Hepatitis Day campaign which will be displayed during the event, please create your own poster using this link and send it to info@ice-hbv.org or tweet @ICE_HBV
All events related to World Hepatitis Day in Victoria can be found on Hepatitis Victoria website.
ICE-HBV manifesto was selected as one of the 180 scientific findings published in 2016 that editors believe could have the greatest impact on society’s most pressing problems.
It is free-access until the end of July on:
Following ICE-HBV’s request to Anthony Fauci to consider strengthening HBV research programmes and subsequent discussions, we received the following statement from John J. McGowan, Ph.D., Deputy Director for Science Management at NIAID:
We at the National Institute of Allergy and Infectious Diseases (NIAID) agree that chronic hepatitis B infection remains a major problem globally. In the United States as well as in other developed and developing countries, too few are vaccinated. The result is that millions with chronic disease will require treatment to prevent end-stage liver disease, cancer and an early death. NIAID supports a broad hepatitis B research portfolio, including basic research supported through R01 and R21 grants, drug and animal model development through small business grants, and the availability of a comprehensive array of preclinical services. In addition, NIAID has a current initiative PAR-14-255 (Multidisciplinary Studies of HIV and Viral Hepatitis Co-infection) with a final receipt date in May of 2017. NIAID also has two new concepts that were approved by the NIAID Advisory Council in January 2017:
You also should be aware of the SBIR initiative launched by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) entitled “New Technologies for Viral Hepatitis SBIR (R43/R44)”.
(NIAID staff) will continue to work with you to address the challenges we face as a community.
ICE-HBV Governing Board will keep approaching research institutes and foundations to request a scaling-up of HBV research programmes worldwide.